Adoptive cell therapies in thoracic malignancies
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Link
https://link.springer.com/content/pdf/10.1007/s00262-022-03142-3.pdf
Reference171 articles.
1. Schabath MB, Cote ML (2019) Cancer progress and priorities: lung cancer. Cancer Epidemiol Prev Biomark. Am Assoc Cancer Res 28:1563–1579.
2. Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L et al (2019) Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res Off J Am Assoc Cancer Res 25:4592–4602
3. Remon J, Aldea M, Besse B, Planchard D, Reck M, Giaccone G et al (2021) Small cell lung cancer: a slightly less orphan disease after immunotherapy. Ann Oncol Off J Eur Soc Med Oncol.
4. Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O et al (2019) Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol 20:239–253
5. Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS et al (2021) First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet Lond Engl 397:375–386
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Autologous CIK cells combined with chemotherapy as the first-line treatment for locally advanced or metastatic gastric cancer is safe and feasible;Frontiers in Immunology;2023-11-01
2. Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy;Cancers;2023-07-23
3. Decoding Roles of Exosomal lncRNAs in Tumor-Immune Regulation and Therapeutic Potential;Cancers;2022-12-31
4. Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence;Korean Journal of Radiology;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3